Incisional hernia

AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device

Retrieved on: 
Thursday, January 25, 2024
Patient, Incisional hernia, General surgery, Abdominal wall, Medicine, Risk, Quality of life, Disease, Food, FDA, Three-body problem, Laparotomy

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its REBUILD Bioabsorbable (“REBUILD”) abdominal wall closure device.

Key Points: 
  • MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its REBUILD Bioabsorbable (“REBUILD”) abdominal wall closure device.
  • REBUILD met the criteria set by the FDA for Breakthrough Devices, potentially providing a novel treatment of an often irreversibly debilitating condition: incisional hernia.
  • Since the first documented laparotomy in 1809, general surgery has been challenged by its limitations in reliably managing a basic but fundamental aspect of abdominal surgery – closure of the abdominal wall.
  • The impact of a failed abdominal closure can be devastating, with lifelong debilitation, morbidity, and re-operation occurring in a large percentage of patients.

SS Innovations Launches Groundbreaking Inaugural Multi-Specialty Robotic Surgical Conference

Retrieved on: 
Monday, January 22, 2024
Aster, Artificial intelligence, General surgery, Urology, Apollo Hospitals, The Honourable, RGCI, Hysterectomy, Cholecystectomy, Medanta, OTC, Conference, Hospital, Cystectomy, Mantra, Incisional hernia, Medical device

FORT LAUDERDALE, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, is proud to have presented the inaugural SS Innovations Multi-Specialty Robotic Surgical Conference (SMRSC), that was held at The Leela Ambience Hotel in Gurugram, Haryana, India on January 19 and 20, 2024. The meeting was highly attended with more than 600 visitors over the course of two days.

Key Points: 
  • 13 Live, broadcasted surgeries were performed by distinguished multi-specialty surgeons, using the SSi Mantra Surgical Robotic System
    Distinguished guests included the Honorable Governor of Haryana, Mr. Bandaru Dattatreya
    FORT LAUDERDALE, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, is proud to have presented the inaugural SS Innovations Multi-Specialty Robotic Surgical Conference (SMRSC), that was held at The Leela Ambience Hotel in Gurugram, Haryana, India on January 19 and 20, 2024.
  • SMRSC 2024 was a transformative event that brought together global medical experts, technological innovators, and visionaries to explore the future of robotic surgery, with a specific focus on SS Innovations’ flagship surgical robotic system, the SSi Mantra.
  • SMRSC 2024 was a productive and educational event that showcased the SSi Mantra, SS Innovations’ technologically advanced, affordable, and accessible surgical robotic system, and SSi Maya, our groundbreaking virtual and mixed reality development division that we anticipate will allow us to launch robotic programs using tele-proctoring and tele-surgery.
  • The conference endeavors to set the stage for the future of healthcare with the SSi Mantra Surgical Robotic System.

Global Hernia Mesh Devices Market Size, Share & Trends Analysis Report 2023: Market to Reach $8.3 Billion by 2030 - Innovation in Enhancing Patient Outcomes Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, October 13, 2023
Medical Supplies, Medical Devices, Health, Surgery, General Health, Biotechnology, Incidence, Femoral hernia, Hernia, Capillary action through synthetic mesh, Prevalence, Inguinal hernia, USD, Biomesh, Growth, Incisional hernia, Operation Time, Patient, Thermoplastic, Pharmaceutical industry

The "Hernia Mesh Devices Market Size, Share & Trends Analysis Report By Hernia Type (Inguinal Hernia, Incisional Hernia, Femoral Hernia), By Mesh Type (Biologic Mesh, Synthetic Mesh), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hernia Mesh Devices Market Size, Share & Trends Analysis Report By Hernia Type (Inguinal Hernia, Incisional Hernia, Femoral Hernia), By Mesh Type (Biologic Mesh, Synthetic Mesh), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global hernia mesh devices market size is expected to reach USD 8.3 billion by 2030.
  • Additionally, the market benefits from a favorable reimbursement scenario, which encourages patients to opt for hernia surgeries, further boosting market growth.
  • Among hernia types, inguinal hernia repair devices hold a substantial market share, thanks to the wide range of available mesh products designed specifically for inguinal repair.

Deep Blue Medical Advances Announces FDA Clearance for Sublay Application in Hernia Surgery, Enabling Broader Use of T-Line Hernia Mesh

Retrieved on: 
Monday, December 5, 2022
Recurrence, Deep Blue Sea (1999 film), Hernia, Food, Weakness, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Randomized controlled trial, FDA, Incisional hernia, Surgeon, Multimedia, Pharmaceutical industry, Thermoplastic

The sublay procedure is the most widely performed open surgery ventral hernia repair method for large incisional hernias.

Key Points: 
  • The sublay procedure is the most widely performed open surgery ventral hernia repair method for large incisional hernias.
  • Deep Blue's T-Line mesh design includes novel mesh extensions that provide superior anchor strength designed to prevent mesh fixation failure.
  • (2004) Oct;240(4):578-83
    About Deep Blue Medical Advances:Established in 2015, Deep Blue Medical Advances is dedicated to addressing the unacceptably high rate of hernia recurrence and providing surgeons a superior surgical experience.
  • Deep Blue Medical is commercializing T-LineHernia Mesh and has a portfolio of additional hernia and surgical products in development.

TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Presentations at SAGES 2021

Retrieved on: 
Monday, August 16, 2021
NASDAQ, MBA, U.S. Securities and Exchange Commission, Inguinal, Sheep, Weakness, CEO, Robot-assisted surgery, Maintenance, Society, Risk, Private Securities Litigation Reform Act, Surgical mesh, Scleral reinforcement surgery, Society of American Gastrointestinal and Endoscopic Surgeons, Patient, COVID-19, GLOBE, Use, Rebar, Research, Marketing, Annual report, Security (finance), Inguinal hernia surgery, Matrix, Abdominal wall, Surgeon, Incisional hernia, Hernia, PRS, FACS, Medical imaging, Medical device, Glass fiber

(NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced three upcoming poster presentations on its OviTex Reinforced Tissue Matrix portfolio.

Key Points: 
  • (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced three upcoming poster presentations on its OviTex Reinforced Tissue Matrix portfolio.
  • Designed by leading experts, with collaboration from more than 100 surgeons, OviTex Reinforced Tissue Matrix is an advanced hernia repair technology that utilizes naturally sourced tissue reinforced with interwoven polymer fibers to facilitate tissue remodeling while optimizing strength and minimizing the foreign body inflammatory response.
  • TELA Bio's OviTex and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
  • OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists.

TELA Bio Initiates BRAVO II Study of OviTex® for the Robotic Repair of Ventral Hernias

Retrieved on: 
Wednesday, May 19, 2021
Hernias, Clinical medicine, Medicine, Incisional hernia, Surgery

"With the continued success of our original BRAVO study and the ongoing evolution in robotic procedures for more complex ventral hernia repair, we are excited to demonstrate the efficacy and durability of the expanded OviTex portfolio in robotic hernia repair through our BRAVO II study.

Key Points: 
  • "With the continued success of our original BRAVO study and the ongoing evolution in robotic procedures for more complex ventral hernia repair, we are excited to demonstrate the efficacy and durability of the expanded OviTex portfolio in robotic hernia repair through our BRAVO II study.
  • This study will include the addition of OviTex LPR, which has been designed specifically for optimal robot compatibility.
  • "\nThe company expects to enroll up to 100 subjects in the BRAVO II study at up to seven US-based sites, with patient follow-up at 90 days, 12 months, and 24 months.
  • Study researchers will primarily monitor the incidence of early postoperative surgical site occurrences, wound-related events, and other complications within three months of surgery.

nanoMesh™ LLC (a subsidiary of Exogenesis Corporation) Announces First-In-Man Clinical Implantation of nanoMesh™

Retrieved on: 
Wednesday, April 21, 2021
Hernias, Anatomy, Clinical medicine, Medicine, Nanomesh, Incisional hernia, Abdominal wall

b'BILLERICA, Mass., April 21, 2021 /PRNewswire/ --nanoMesh LLC,a subsidiary ofExogenesis Corporation, announced today that it has successfully initiated First-In-Man implantation of its proprietary soft tissue repair device, Exogenesis nanoMesh.

Key Points: 
  • b'BILLERICA, Mass., April 21, 2021 /PRNewswire/ --nanoMesh LLC,a subsidiary ofExogenesis Corporation, announced today that it has successfully initiated First-In-Man implantation of its proprietary soft tissue repair device, Exogenesis nanoMesh.
  • He underwent a ventral hernia repair utilizing an Exogenesis nanoMesh placed in the retrorectus position, and the defect was closed.
  • nanoMesh possesses a unique nanometer-level surface texture, via the application of Accelerated Neutral Atom Beam (ANAB) technology1 during manufacturing.
  • nanoMesh is indicated for the repair of abdominal wall hernias and abdominal wall deficiencies that require the addition of reinforcing material to obtain the desired surgical result.

TELA Bio Announces 12-Month Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair

Retrieved on: 
Thursday, March 18, 2021
Clinical medicine, Medicine, Medical specialties, Hernias, Digestive system surgery, Hernia repair, Surgical mesh, Surgery, Breast surgery, Inguinal hernia surgery, Incisional hernia

The analysis includes the full patient cohort at the 12-month follow-up and an interim cohort at the 24-month follow-up.

Key Points: 
  • The analysis includes the full patient cohort at the 12-month follow-up and an interim cohort at the 24-month follow-up.
  • The final 12-month analysis includes 76 patients, of whom two patients experienced a recurrence, both adjacent to the original repair, with the OviTex repairs remaining intact.
  • TELA Bio's OviTex and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
  • OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists.

TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair

Retrieved on: 
Friday, September 25, 2020
Hernias, Clinical medicine, Medicine, Anatomy, Incisional hernia, Surgery

The first poster titled, "Surgical site infections and occurrences (SSIs & SSOs) after ventral hernia repair (VHR) with reinforced tissue matrix (RTM), 30-day data from the BRAVO study," demonstrated that ventral hernia repair using OviTex led to a low incidence of surgical site infections and occurrences.

Key Points: 
  • The first poster titled, "Surgical site infections and occurrences (SSIs & SSOs) after ventral hernia repair (VHR) with reinforced tissue matrix (RTM), 30-day data from the BRAVO study," demonstrated that ventral hernia repair using OviTex led to a low incidence of surgical site infections and occurrences.
  • The study consisted of 85 subjects, of which 75% met the criteria for Ventral Hernia Working Group (VHWG) grade 2 or grade 3.
  • The second poster, "Final outcomes of the initial 20 subjects reaching two year follow up in the BRAVO Ventral Hernia Study," is the first look at long-term outcomes data for the initial 20 patients who had ventral hernia repair using OviTex.
  • "We continue to be encouraged by the BRAVO Study data presented at this year's Americas Hernia Society Annual Meeting," said Antony Koblish, President and CEO of TELA Bio.

Hernia Repair Devices and Consumables Market to Reach $6.35 Bn, Globally, by 2027 at 3.6% CAGR: AMR

Retrieved on: 
Monday, July 13, 2020
Hernias, Medicine, Anatomy, Clinical medicine, Hernia repair, Inguinal hernia, Femoral hernia, Incisional hernia, Umbilical hernia, Inguinal, Inguinal hernia surgery, Biomesh

PORTLAND, Oregon, July 13, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, " Hernia Repair Devices and Consumables Market by Product (Fixation Devices and Consumables), Surgery Type (Open Tension-Free Repair Surgery and Laparoscopic surgery), and Hernia Type (Incisional Hernia, Umbilical, Inguinal Hernia, and Femoral Hernia): Global Opportunity Analysis and Industry Forecast, 20202027."

Key Points: 
  • PORTLAND, Oregon, July 13, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, " Hernia Repair Devices and Consumables Market by Product (Fixation Devices and Consumables), Surgery Type (Open Tension-Free Repair Surgery and Laparoscopic surgery), and Hernia Type (Incisional Hernia, Umbilical, Inguinal Hernia, and Femoral Hernia): Global Opportunity Analysis and Industry Forecast, 20202027."
  • According to the report, the global hernia repair devices and consumables industry generated $4.74 billion in 2019, and is projected to garner $6.35 billion by 2027, witnessing a CAGR of 3.6% from 2020 to 2027.
  • Rise in advanced meshes demand, surge in implementation of robotic surgeries, and increase in number of hernia patients drive the global hernia repair devices and consumables market.
  • The demand for hernia repair devices and consumables has significantly dropped during the coronavirus pandemic.